melatonin has been researched along with Bone Loss, Osteoclastic in 19 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bone resorption is reduced by increased synthesis of osteoprogeterin (OPG), a decoy receptor that prevents receptor activator of NK-κB ligand (RANKL) in binding to its receptor." | 2.49 | Melatonin and the skeleton. ( Amstrup, AK; Mosekilde, L; Rejnmark, L; Sikjaer, T, 2013) |
| "The melatonin treatment group showed a reduction in osteoclastogenesis transcription factors and ATP6v0d2 gene expression." | 1.72 | Melatonin Attenuates RANKL-Induced Osteoclastogenesis via Inhibition of Atp6v0d2 and DC-STAMP through MAPK and NFATc1 Signaling Pathways. ( Jeong, SP; Kim, IR; Kim, SS; Park, BS, 2022) |
| "Melatonin treatment effectively blocked RANKL-induced osteoclastogenesis by inhibiting PRMT1 and asymmetric dimethylarginine (ADMA) expression." | 1.62 | Melatonin Inhibits Osteoclastogenesis and Bone Loss in Ovariectomized Mice by Regulating PRMT1-Mediated Signaling. ( Choi, JH; Jang, AR; Kim, DI; Park, JH; Park, MJ, 2021) |
| "Melatonin is a neurohormone involved in bone homeostasis." | 1.56 | Melatonin up-regulates bone marrow mesenchymal stem cells osteogenic action but suppresses their mediated osteoclastogenesis via MT ( Ding, D; Si, J; Wang, B; Wang, C; Wang, H; Zhang, D; Zhang, J; Zhou, Y, 2020) |
| "To examine these influences on bone resorption, we collected 48-h sequential urine samples under both ambulatory (8-h sleep:16-h wake) and constant routine (CR) (constant wake, posture, nutrition and dim light) conditions from 20 healthy premenopausal women." | 1.51 | Relationship between melatonin and bone resorption rhythms in premenopausal women. ( Gooley, JJ; Lockley, SW; Rahman, SA; St Hilaire, MA; Witt-Enderby, PA, 2019) |
| "Melatonin treatment significantly stimulated Calcitonin (an osteoclast-inhibiting hormone) mRNA expression and decreased the mRNA expression of receptor activator of nuclear factor κB ligand (a promoter of osteoclastogenesis), which coincided with suppressed gene expression levels for osteoclast functions." | 1.51 | Melatonin is a potential drug for the prevention of bone loss during space flight. ( Akatsuka, R; Ando, H; Chowdhury, VS; Ejiri, S; Endo, M; Funahashi, H; Furusawa, Y; Hanmoto, T; Hattori, A; Hayakawa, K; Hayashi, A; Hirayama, J; Ijiri, K; Ikari, T; Ikegame, M; Iseki, H; Kambegawa, A; Kaminishi, A; Kitamura, KI; Kondo, T; Maeda, M; Maruyama, Y; Matsuda, K; Matsuoka, R; Mikuni-Takagaki, Y; Mishima, H; Nakamura, M; Nakano, M; Nakashima, H; Nara, M; Nishiuchi, T; Omori, K; Sasayama, Y; Seki, A; Sekiguchi, T; Shimazu, T; Shimizu, N; Somei, M; Suzuki, H; Suzuki, N; Suzuki, T; Tabata, MJ; Tabuchi, Y; Takahashi, A; Takasaki, I; Takeuchi, T; Taya, T; Uchida, H; Wada, S; Watanabe, Y; Yamamoto, T; Yano, S; Yashima, S, 2019) |
| "Osteoporosis is closely associated with the dysfunction of bone metabolism, which is caused by the imbalance between new bone formation and bone resorption." | 1.51 | MicroRNA-92b-5p modulates melatonin-mediated osteogenic differentiation of bone marrow mesenchymal stem cells by targeting ICAM-1. ( Bamba, D; Bi, Z; Cai, B; Ding, F; Feng, C; Fu, Y; Gao, M; Gong, R; He, M; Huang, Q; Jin, M; Li, Y; Liu, T; Ma, W; Reiters, R; Sukhareva, N; Sun, Y; Xu, C; Yan, G; Yang, F; Yang, L; Yuan, Y; Zhang, L, 2019) |
| "Melatonin has been known to promote osteoblast differentiation and bone maturation, but a direct role of melatonin on osteoclast differentiation is still elusive." | 1.46 | Suppression of Osteoclastogenesis by Melatonin: A Melatonin Receptor-Independent Action. ( Bae, MK; Kim, HJ; Kim, YD, 2017) |
| "Because bone resorption is an essential requirement for adequate remodeling during fracture healing, we conclude that melatonin impairs fracture healing by suppressing bone resorption through down-regulation of RANKL-mediated osteoclast activation." | 1.38 | Melatonin impairs fracture healing by suppressing RANKL-mediated bone remodeling. ( Anton, C; Garcia, P; Histing, T; Holstein, JH; Klein, M; Matthys, R; Menger, MD; Pohlemann, T; Scheuer, C, 2012) |
| "This treatment significantly reduced bone resorption parameters (i." | 1.31 | Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. ( Kaku, T; Koyama, H; Lau, KH; Nakade, O; Takada, Y, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 6 (31.58) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, SS | 1 |
| Jeong, SP | 1 |
| Park, BS | 1 |
| Kim, IR | 1 |
| Zhou, Y | 1 |
| Wang, C | 1 |
| Si, J | 1 |
| Wang, B | 1 |
| Zhang, D | 1 |
| Ding, D | 1 |
| Zhang, J | 1 |
| Wang, H | 1 |
| Liu, PI | 1 |
| Chang, AC | 1 |
| Lai, JL | 1 |
| Lin, TH | 1 |
| Tsai, CH | 1 |
| Chen, PC | 1 |
| Jiang, YJ | 1 |
| Lin, LW | 1 |
| Huang, WC | 1 |
| Yang, SF | 1 |
| Tang, CH | 1 |
| Choi, JH | 1 |
| Jang, AR | 1 |
| Park, MJ | 1 |
| Kim, DI | 1 |
| Park, JH | 1 |
| Jarrar, H | 1 |
| Çetin Altındal, D | 1 |
| Gümüşderelioğlu, M | 1 |
| Wu, X | 2 |
| Qiao, S | 1 |
| Wang, W | 1 |
| Zhang, Y | 1 |
| Shi, J | 2 |
| Zhang, X | 2 |
| Gu, W | 1 |
| Li, Y | 2 |
| Ding, X | 1 |
| Wei, J | 1 |
| Gu, Y | 2 |
| Lai, H | 1 |
| Kim, HJ | 2 |
| Bae, MK | 1 |
| Kim, YD | 1 |
| Ping, Z | 1 |
| Wang, Z | 1 |
| Wang, L | 1 |
| Guo, X | 1 |
| Zhou, W | 1 |
| Hu, X | 1 |
| Liu, Y | 1 |
| Zhang, W | 1 |
| Yang, H | 1 |
| Xu, Y | 1 |
| Geng, D | 1 |
| St Hilaire, MA | 1 |
| Rahman, SA | 1 |
| Gooley, JJ | 1 |
| Witt-Enderby, PA | 1 |
| Lockley, SW | 1 |
| Ikegame, M | 1 |
| Hattori, A | 1 |
| Tabata, MJ | 1 |
| Kitamura, KI | 1 |
| Tabuchi, Y | 1 |
| Furusawa, Y | 1 |
| Maruyama, Y | 1 |
| Yamamoto, T | 1 |
| Sekiguchi, T | 1 |
| Matsuoka, R | 1 |
| Hanmoto, T | 1 |
| Ikari, T | 1 |
| Endo, M | 1 |
| Omori, K | 1 |
| Nakano, M | 1 |
| Yashima, S | 1 |
| Ejiri, S | 1 |
| Taya, T | 1 |
| Nakashima, H | 1 |
| Shimizu, N | 1 |
| Nakamura, M | 1 |
| Kondo, T | 1 |
| Hayakawa, K | 1 |
| Takasaki, I | 1 |
| Kaminishi, A | 1 |
| Akatsuka, R | 1 |
| Sasayama, Y | 1 |
| Nishiuchi, T | 1 |
| Nara, M | 1 |
| Iseki, H | 1 |
| Chowdhury, VS | 1 |
| Wada, S | 1 |
| Ijiri, K | 1 |
| Takeuchi, T | 1 |
| Suzuki, T | 1 |
| Ando, H | 1 |
| Matsuda, K | 1 |
| Somei, M | 1 |
| Mishima, H | 1 |
| Mikuni-Takagaki, Y | 1 |
| Funahashi, H | 1 |
| Takahashi, A | 1 |
| Watanabe, Y | 1 |
| Maeda, M | 1 |
| Uchida, H | 1 |
| Hayashi, A | 1 |
| Kambegawa, A | 1 |
| Seki, A | 1 |
| Yano, S | 1 |
| Shimazu, T | 1 |
| Suzuki, H | 1 |
| Hirayama, J | 1 |
| Suzuki, N | 1 |
| Feng, C | 1 |
| Gao, M | 1 |
| Jin, M | 1 |
| Liu, T | 1 |
| Yuan, Y | 1 |
| Yan, G | 1 |
| Gong, R | 1 |
| Sun, Y | 1 |
| He, M | 1 |
| Fu, Y | 1 |
| Zhang, L | 1 |
| Huang, Q | 1 |
| Ding, F | 1 |
| Ma, W | 1 |
| Bi, Z | 1 |
| Xu, C | 1 |
| Sukhareva, N | 1 |
| Bamba, D | 1 |
| Reiters, R | 1 |
| Yang, F | 1 |
| Cai, B | 1 |
| Yang, L | 1 |
| Amstrup, AK | 1 |
| Sikjaer, T | 1 |
| Mosekilde, L | 1 |
| Rejnmark, L | 1 |
| Vriend, J | 1 |
| Reiter, RJ | 1 |
| Calvo-Guirado, JL | 1 |
| Gómez-Moreno, G | 1 |
| López-Marí, L | 1 |
| Guardia, J | 1 |
| Marínez-González, JM | 1 |
| Barone, A | 1 |
| Tresguerres, IF | 1 |
| Paredes, SD | 1 |
| Fuentes-Breto, L | 1 |
| Histing, T | 1 |
| Anton, C | 1 |
| Scheuer, C | 1 |
| Garcia, P | 1 |
| Holstein, JH | 1 |
| Klein, M | 1 |
| Matthys, R | 1 |
| Pohlemann, T | 1 |
| Menger, MD | 1 |
| Egermann, M | 1 |
| Gerhardt, C | 1 |
| Barth, A | 1 |
| Maestroni, GJ | 1 |
| Schneider, E | 1 |
| Alini, M | 1 |
| Ostrowska, Z | 1 |
| Wołkowska-Pokrywa, K | 1 |
| Kos-Kudła, B | 1 |
| Swietochowska, E | 1 |
| Marek, B | 1 |
| Kajdaniuk, D | 1 |
| Ladizesky, MG | 1 |
| Cutrera, RA | 1 |
| Boggio, V | 1 |
| Somoza, J | 1 |
| Centrella, JM | 1 |
| Mautalen, C | 1 |
| Cardinali, DP | 1 |
| Koyama, H | 1 |
| Nakade, O | 1 |
| Takada, Y | 1 |
| Kaku, T | 1 |
| Lau, KH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessing the Efficacy of Melatonin on Bone Health in Peri-menopausal Women[NCT01152580] | Phase 1 | 19 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Innovative Technology for Assessing the Periodontal Disease and New Periodontitis Treatment Based on Hyaluronic Acid and Melatonin[NCT03656484] | Phase 2 | 50 participants (Actual) | Interventional | 2019-01-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The mean change in bone mineral density (BMD), represented by T-scores, was assessed by calcaneal ultrasound in women taking melatonin (3 mg) or placebo nightly at baseline and after 6 months. A T-score is a comparison of a subject's BMD to that of a healthy 30 year old female of the same ethnicity. The more negative the T-score, the worse the BMD. Osteoporosis or brittle bone disease is defined as a T-score -2.5 or less. A more negative mean change in a T-score would indicate a worsening of BMD. A more positive mean change in a T-score would indicate an improvement of BMD. (NCT01152580)
Timeframe: Baseline and 6 months
| Intervention | T-score (Mean) |
|---|---|
| Sugar Pill | -0.02 |
| Melatonin | 0.05 |
"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | 0.1 |
| Melatonin | -0.6 |
"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | -0.2 |
| Melatonin | -0.4 |
"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | -0.7 |
| Melatonin | -0.4 |
"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | -0.2 |
| Melatonin | 0.4 |
Osteocalcin is a measure of osteoblast activity because it is secreted from osteoblasts. Osteocalcin levels were measured in the serum of women at baseline and after 6 months of taking placebo or melatonin (3 mg) and the data are reported as ng/mL. Osteoblasts are bone-forming cells so a more positive mean change in osteoblast activity over time (6 months - baseline) could indicate an improvement in bone mineral density. A more negative mean change in osteocalcin levels over time (6 months - baseline) could indicate a worsening of bone mineral density. (NCT01152580)
Timeframe: Baseline and 6 months
| Intervention | ng/mL (Mean) |
|---|---|
| Sugar Pill | -0.6 |
| Melatonin | 1.83 |
Type-1 collagen cross-linked N-telopeptide (NTX) levels were measured in the serum of women at baseline and after taking placebo or melatonin (3 mg) nightly for 6 months. NTX, reported as bone collagen equivalents (BCE), is released from bone due to the actions of osteoclasts or bone breakdown cells. A more positive mean change in NTX levels (6 months - baseline) could result in a worsening of bone mineral density due to an increase in bone breakdown whereas a more negative mean change in NTX levels could result in an improvement in bone mineral density due to a decrease in bone breakdown. (NCT01152580)
Timeframe: Baseline and 6 months
| Intervention | nM BCE (Mean) |
|---|---|
| Sugar Pill | -0.36 |
| Melatonin | -0.32 |
"Pittsburgh Sleep Quality Index (PSQI) Questionnaire is a validated questionnaire that assesses the quality and quantity of sleep and sleep disorders.This survey is designed to identify good and poor sleepers and has a score scale that ranges from 0-21 with 0 being good quality of sleep and 21 being poor quality of sleep and/or indicating as having a sleep disorder. A more positive mean change in the PSQI over time indicates a worsening of sleep. A more negative mean change in the PSQI over time indicates an improvement in sleep." (NCT01152580)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Sugar Pill | -1.0 |
| Melatonin | -0.5 |
3 reviews available for melatonin and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Melatonin and the skeleton.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Circadian Rhythm; Diseas | 2013 |
Melatonin, bone regulation and the ubiquitin-proteasome connection: A review.
Topics: Animals; Bone and Bones; Bone Diseases; Bone Resorption; Circadian Rhythm; Humans; Melatonin; NF-kap | 2016 |
[Melatonin and bone status].
Topics: Animals; Bone and Bones; Bone Density; Bone Resorption; Female; Humans; Melatonin; Osteoblasts; Oste | 2006 |
16 other studies available for melatonin and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Melatonin Attenuates RANKL-Induced Osteoclastogenesis via Inhibition of Atp6v0d2 and DC-STAMP through MAPK and NFATc1 Signaling Pathways.
Topics: Animals; Antioxidants; Bone Resorption; Cell Differentiation; Cells, Cultured; Down-Regulation; Gene | 2022 |
Melatonin up-regulates bone marrow mesenchymal stem cells osteogenic action but suppresses their mediated osteoclastogenesis via MT
Topics: Animals; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Melatonin; Mesenchymal Stem Cells | 2020 |
Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases.
Topics: Animals; Bone Marrow Cells; Bone Neoplasms; Bone Resorption; Cell Differentiation; Disease Models, A | 2021 |
Melatonin Inhibits Osteoclastogenesis and Bone Loss in Ovariectomized Mice by Regulating PRMT1-Mediated Signaling.
Topics: Animals; Bone Diseases, Metabolic; Bone Resorption; Cell Differentiation; Cells, Cultured; Down-Regu | 2021 |
Effect of melatonin/BMP-2 co-delivery scaffolds on the osteoclast activity.
Topics: Animals; Biocompatible Materials; Bone Morphogenetic Protein 2; Bone Regeneration; Bone Resorption; | 2021 |
Melatonin prevents peri‑implantitis via suppression of TLR4/NF-κB.
Topics: Alveolar Bone Loss; Animals; Bone Resorption; Melatonin; NF-kappa B; Osteoclasts; Osteogenesis; Peri | 2021 |
Suppression of Osteoclastogenesis by Melatonin: A Melatonin Receptor-Independent Action.
Topics: Animals; Bone Resorption; Cell Differentiation; Gene Expression; Gene Silencing; Macrophages; Melato | 2017 |
Inhibitory effects of melatonin on titanium particle-induced inflammatory bone resorption and osteoclastogenesis via suppression of NF-κB signaling.
Topics: Animals; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Inflammation; Male; MAP Kinase Si | 2017 |
Relationship between melatonin and bone resorption rhythms in premenopausal women.
Topics: Adult; Biomarkers; Bone Resorption; Circadian Rhythm; Collagen Type I; Female; Humans; Light; Melato | 2019 |
Melatonin is a potential drug for the prevention of bone loss during space flight.
Topics: Animals; Bone Density; Bone Resorption; Calcitonin; Cell Differentiation; Goldfish; Immunohistochemi | 2019 |
MicroRNA-92b-5p modulates melatonin-mediated osteogenic differentiation of bone marrow mesenchymal stem cells by targeting ICAM-1.
Topics: Bone Resorption; Cell Differentiation; Cell Line; Humans; Intercellular Adhesion Molecule-1; Melaton | 2019 |
Actions of melatonin mixed with collagenized porcine bone versus porcine bone only on osteointegration of dental implants.
Topics: Analysis of Variance; Animals; Bone Resorption; Bone Transplantation; Calcium; Collagen; Dental Impl | 2010 |
Melatonin impairs fracture healing by suppressing RANKL-mediated bone remodeling.
Topics: Animals; Biomechanical Phenomena; Bone Remodeling; Bone Resorption; Collagen Type I; Dose-Response R | 2012 |
Pinealectomy affects bone mineral density and structure--an experimental study in sheep.
Topics: Animals; Biomarkers; Bone Density; Bone Resorption; Disease Models, Animal; Female; Ilium; Melatonin | 2011 |
Effect of melatonin on bone metabolism in ovariectomized rats.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Amino Acids; Animals; Bone and Bones; Bone Density; Bo | 2001 |
Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
Topics: Animals; Bone Density; Bone Resorption; Carrier Proteins; Cell Line; Down-Regulation; Gene Expressio | 2002 |
Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
Topics: Animals; Bone Density; Bone Resorption; Carrier Proteins; Cell Line; Down-Regulation; Gene Expressio | 2002 |
Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
Topics: Animals; Bone Density; Bone Resorption; Carrier Proteins; Cell Line; Down-Regulation; Gene Expressio | 2002 |
Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
Topics: Animals; Bone Density; Bone Resorption; Carrier Proteins; Cell Line; Down-Regulation; Gene Expressio | 2002 |